We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Covering thalidomide, lenalidomide, and pomalidomide: temporary guidance for pregnancy prevention arrangements for patients taking them during COVID-19
New monitoring instructions to detect these side effects as soon as possible.
Before starting treatment with pomalidomide, establish hepatitis B virus status in all patients.
Guidance has been published about thalidomide, lenalidomide, and pomalidomide and the use of remote consultations and home pregnancy testing for patients taking them during COVID-19.
Information for patients, healthcare professionals and developers of new medicines
A. Menarini Farmaceutica Internazionale Srl is recalling a specific batch as a precautionary measure due to the distribution of Invokana 300mg in Northern Ireland in packaging intended for the Greek market.
Employment Appeal Tribunal Judgment of Mrs Justice Eady on 18 April 2024.
Employment Appeal Tribunal Judgment of Judge Shanks on 16 April 2024.
medac GmbH (t/a medac Pharma LLP) is recalling the product for the batch specified in this notification due to particles detected during long-term stability tests.
Product Safety Report for Esapharma Movate Steroid Cream presenting a serious chemical risk.
This guidance covers ‘grandfathering’ and managing the lifecycle changes of medicinal products.
Statement by Ambassador Barbara Woodward at the UN Security Council meeting on Libya.
Product Safety Report for SIVOP Parfums & Cosmétiques Clair-Liss Lightening Body Cream presenting a serious chemical risk.
Safety leaflet on topical corticosteroids and withdrawal reactions to help patients and their carers to use these medicines safely.
Product Safety Report for Skin Gard Lightening Lotion presenting a serious chemical risk.
Check the tariff classification for bones with some meat, fat and tendons (so called soup bones).
Check the tariff classification for surface-active preparation for washing the skin and the hair (gel 2-in-1).
Check the tariff classification for dried buffalo ears and dried beef meat scraped off from the throat, for use as animal feed.
In April 2016, letters were sent regarding canagliflozin (Invokana▼, Vokanamet▼), BCR-ABL tyrosine kinase inhibitors, pomalidomide (Imnovid▼), and retigabine (Trobalt)
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.